SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

CORRESP Filing

AETHLON MEDICAL INC
Date: Aug. 29, 2025 · CIK: 0000882291 · Accession: 0001683168-25-006557

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-289745

Date
August 29, 2025
Author
MAXIM GROUP LLC
Form
CORRESP
Company
AETHLON MEDICAL INC

Letter

Re: Aethlon Medical, Inc. Registration Statement on Form S-1, as amended File No. 333-289745

MAXIM GROUP LLC

300 Park Avenue, 16 th Floor New York, New York 10022

August 29, 2025

VIA EDGAR CORRESPONDENCE

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E. Washington, D.C. 20549

Ladies and Gentlemen:

Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), we, the underwriter, hereby request that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced registration statement on Form S-1 (the "Registration Statement") to become effective at 5:01 p.m., Eastern time, on Tuesday, September 2, 2025, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated August 29, 2025 to agents, dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

The undersigned, as underwriter, has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. If you require any additional information with respect to this letter, please contact M. Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

Very truly yours,
MAXIM GROUP LLC

Show Raw Text
CORRESP
 1
 filename1.htm

 MAXIM GROUP LLC

 300 Park Avenue, 16 th Floor
New York, New York 10022

 August 29, 2025

 VIA EDGAR CORRESPONDENCE

 U.S. Securities and Exchange Commission

 Division of Corporation Finance

 100 F Street, N.E. Washington, D.C. 20549

 Re: Aethlon Medical, Inc.
Registration Statement on Form S-1, as amended
 File No. 333-289745

 Ladies and Gentlemen:

 Pursuant to Rule 461 of the
General Rules and Regulations under the Securities Act of 1933, as amended (the "Act"), we, the underwriter, hereby request
that the Securities and Exchange Commission (the "Commission") take appropriate action to cause the above-referenced registration
statement on Form S-1 (the "Registration Statement") to become effective at 5:01 p.m., Eastern time, on Tuesday, September
2, 2025, or as soon thereafter as practicable.

 Pursuant to Rule 460 under
the Act, we wish to advise you that we have distributed as many copies of the Preliminary Prospectus dated August 29, 2025 to agents,
dealers, institutions and others as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

 The undersigned, as underwriter,
has complied and will comply with Rule 15c2-8 under the Securities Exchange Act of 1934, as amended. If you require any additional information
with respect to this letter, please contact M. Ali Panjwani at (212) 326-0820 of Pryor Cashman LLP.

 Very truly yours,

 MAXIM GROUP LLC

 By: /s/ Ritesh M. Veera
 Ritesh M. Veera
 Co-Head of Investment Banking

 cc: M. Ali Panjwani, Esq.
 Pryor Cashman LLP